Skip to main content

Table 4 Reanalysis for the effects of inulin-type fructans on glycemic indicators (FBG, HbA1c, FINS and HOMA-IR) excluding high heterogeneity studies

From: Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose–response meta-analysis of 33 randomized controlled trials

SubgroupsaFBG (mmol/l)HbA1c (%)FINS (μU/ml)HOMA-IR
nWMD (95% CI)PbI2 (%)PcnWMD (95% CI)PbI2 (%)PcnWMD (95% CI)PbI2 (%)PcnWMD (95% CI)PbI2 (%)Pc
Healthy-subjects5− 0.04 (− 0.18, 0.09)0.5130.00.447     5− 0.10 (− 1.29, 1.10)0.87459.80.0412− 0.76 (− 1.53, 0.02)0.0560.00.830
T2DM and prediabetes11− 0.58 (− 0.86, − 0.31)< 0.0010.00.6727− 0.37 (− 0.71, − 0.02)0.03618.70.2878− 1.14 (− 2.05, − 0.23)0.01449.70.0526− 0.47 (− 0.64, − 0.30)< 0.00139.30.143
Overweight and obesity7− 0.08 (− 0.18, 0.02)0.1260.00.748     5− 1.54 (− 3.11, 0.03)0.0540.00.8443− 0.38 (− 1.20, 0.43)0.3530.00.391
Others7− 0.08 (− 0.18, 0.02)0.4190.00.7481− 0.20 (− 0.44, 0.04)0.101~~5− 1.14 (− 1.93, − 0.34)0.0050.00.6554− 0.31 (− 0.55, − 0.08)0.0100.00.883
Total30− 0.10 (− 0.18, − 0.03)0.0054.40.3978− 0.25 (− 0.45, − 0.06)0.01112.50.33323− 0.89 (− 1.50, − 0.28)0.00451.60.00215− 0.43 (− 0.56, − 0.29)< 0.0010.00.553
  1. FBG fasting blood glucose, FINS fasting insulin, HbA1c glycosylated hemoglobin, HOMA-IR homeostasis model assessment- insulin resistance, T2DM type 2 diabetes mellitus
  2. aExcluded trials: FBG: Dehghan [30], Dehghan [29], and Guess [37]; HbA1c: Dehghan [31], Dehghan [29], Gargari [34] and Dewulf [32]; FINS: Dehghan [31], Gargari [34] and Ghavami [35]; HOMA-IR: Dehghan [31], Gargari [34] and Ghavami [35]
  3. bP value for subgroup differences between groups
  4. cP value for heterogeneity within each subgroup
\